Search
Gavorestat
go.drugbank.com/drugs/DB16707InvestigationalGavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).
AZD0543
go.drugbank.com/drugs/DB33982ExperimentalAZD0543 is under investigation in clinical trial NCT07824622 (Study of Safety and PK of AZD0543 in Healthy Adults).
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].
IONIS-FGFR4Rx
go.drugbank.com/drugs/DB16198InvestigationalIONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).
HKI-357
go.drugbank.com/drugs/DB13002InvestigationalHki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).
Fenpropidin
go.drugbank.com/drugs/DB12728ApprovedWithdrawnFenpropidin has been investigated for the treatment of Hernia.
Categories: Compounds used in a research, industrial, or household settingEthyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Categories: Vitamin K AntagonistsIodoxamic acid
go.drugbank.com/drugs/DB13539ExperimentalRadiopaque medium used in the diagnosis of gall bladder & bile duct diseases, usually as meglumine salt.
Categories: Compounds used in a research, industrial, or household settingMerbromin
go.drugbank.com/drugs/DB13392InvestigationalIt is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market
Methacholine
go.drugbank.com/drugs/DB06709Approved[L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR. ⦠[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]